诺瓦瓦克斯医药公司(NVAX)今日盘中股价大幅下跌近6%,引发市场广泛关注。这一暴跌与 NVAX公司近日终止与英国卫生安全局(UKHSA)的 COVID-19 疫苗供应协议直接相关。
根据 NVAX公布的和解协议,为终止与英国卫生安全局的疫苗供应合同,NVAX需要在未来三年内向对方支付高达1.238亿美元的巨额费用。第一笔分期付款更是将在本月底11月30日到期。
此次宣布 NVAX解约将向英国支付庞大费用的消息无疑给公司的财务状况带来了重大阴影。作为一家专注于疫苗研发的生物制药公司,药品供应合同是NVAX重要的收入来源。失去这一重量级合同不仅削弱了公司未来现金流水平,还打击了投资者对公司长期发展前景的信心。因此,NVAX股价应声下跌几乎是情理之中的结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.